Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Ewing Sarcoma
- Osteosarcoma
- Rhabdomyosarcoma
- Soft Tissue Sarcoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 12 years and 30 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02945800
- Collaborators
- National Pediatric Cancer Foundation
- Investigators
- Principal Investigator: Javier E. Oesterheld, M.D. Carolinas Medical Center, Levine Cancer Institute
Get Well Soon